National Marrow Donor Program–Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide

Overview of attention for article published in Journal of Clinical Oncology, April 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 19 news outlets
twitter: 40 X users

patent: 1 patent
guideline: 2 clinical guideline sources

Readers on

mendeley: 107 Mendeley

So far, Altmetric has seen 45 X posts from 40 X users, with an upper bound of 201,861 followers.

@LoriMuffly @sghmd @drkomanduri @DrMonzrAlMalki @ASTCT @Chrislemieux90 @DrMiguelPerales I would go with the best MMUD donor available as long as 4-6/8 match. Youngest would be the best but can follow the criteria in this paper . https://t.co/BMOXYsI4FY

RT @amjimenezmd: @drhusnain01 @MediHumdani @DrMiguelPerales @drkomanduri @uroosaibrahim @EmmanuelKatsani @BeTheMatch @sghmd @BMTCTN https:/…

@drhusnain01 @MediHumdani @DrMiguelPerales @drkomanduri @uroosaibrahim @EmmanuelKatsani @BeTheMatch @sghmd @BMTCTN https://t.co/vPLs8wfxKM

National Marrow Donor Program–Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide | Journal of Clinical Oncology https://t.co/WApyzgr84L

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 41 additional X posts.